Shanghai generics and traditional-medicine maker within the Fosun Pharma group, selling respiratory and other hospital drugs.
Shanghai generics and traditional-medicine maker within the Fosun Pharma group, selling respiratory and other hospital drugs.
In one line: A small Fosun-affiliated generics maker.
Moat: none (distribution). Commodity generics maker without a distinctive patented product line.
Headquarters: Shanghai, China · Employees: 9,697
Size Shanghai Shyndec Pharmaceutical (600420.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.59B, the 1435th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥7.92 on 18 Nov 2026.
Performance Over six months the shares fell 14.5%, against -7.7% for the median peer and -20.0% for the China market (cap-weighted) — 8th lowest of 20 in its peer set.
Growth Revenue fell 13.1% over the last twelve months (peer median +6.8%); the operating margin is 6.2% (peer median 12.4%).
Valuation It trades at 12.6× forward earnings against a peer median of 26.0× (2nd cheapest of 15).
Price implies For today's price to make sense, revenue must grow about -7% a year for seven years (Req g). Recent delivered growth is -6%, so the hurdle is -1 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 0.1 points above its cost of capital (5.2% WACC).
Next results Next results expected around 29 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥8.03B | CN¥9.30B | CN¥10.9B | CN¥12.0B | CN¥12.9B |
| Revenue growth | — | -14% | -9% | -7% | — |
| Gross profit | CN¥2.81B | CN¥2.83B | CN¥4.05B | CN¥4.36B | CN¥4.67B |
| EBITDA | n/a | CN¥1.82B | CN¥2.30B | CN¥1.78B | CN¥1.69B |
| Net income | CN¥451M | CN¥942M | CN¥1.08B | CN¥692M | CN¥628M |
| Free cash flow | CN¥514M | CN¥1.47B | CN¥2.05B | CN¥1.39B | CN¥2.55B |
| Capital expenditure | CN¥201M | CN¥264M | CN¥220M | CN¥357M | CN¥307M |
| Total debt | CN¥1.33B | CN¥1.19B | CN¥1.69B | CN¥1.75B | CN¥3.86B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Shanghai Shyndec Pharmaceutical 600420.SS | $1.59B | -14% | -13% | 6% | 12.6× | -6.6% |
| Shanghai Fosun Pharmaceutical (Group) 600196.SS | $7.57B | -14% | +8% | 6% | 14.8× | 2.9% |
| China Resources Sanjiu Medical & Pharmaceutical 000999.SZ | $6.59B | +6% | +4% | 14% | 13.2× | -6.2% |
| Yunnan Baiyao 000538.SZ | $15.0B | +11% | +5% | 11% | 18.3× | -0.2% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 600420.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -3.9% | -4.5% | 11th highest of 21 |
| 6-month return | -14.5% | -7.7% | 8th lowest of 20 |
| Distance from 52-week high | -28.6% | -33.2% | 10th highest of 21 |
| Revenue growth (TTM) | -13.1% | +6.8% | 5th lowest of 20 |
| Operating margin | 6.2% | 12.4% | 4th lowest of 20 |
| Forward P/E | 12.6× | 26.0× | 2nd cheapest of 15 |
| Growth the price implies (Req g, 7 yrs) | -6.6% | 11.3% | 3rd least demanding of 16 |
| Growth delivered (Del g) | -5.6% | +6.8% | 4th lowest of 16 |
| Hurdle (Req g minus delivered) | -1.0 pp | +7.6 pp | 7th least demanding of 16 |
| ROIC minus cost of capital | +0.1 pp | +1.2 pp | 10th lowest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Shanghai Shyndec Pharmaceutical 600420.SS | China | $1.59B | -14% | -13% | 6% | 12.6× | -6.6% | -5.6% |
| Jubilant Pharmova JUBLPHARMA.NS | India | $1.59B | -8% | +18% | 7% | 29.0× | n/a | n/a |
| Beijing Aosaikang Pharmaceutical 002755.SZ | China | $1.60B | -31% | -13% | 12% | 57.4× | 12.8% | -14.0% |
| Yantai Dongcheng Biochemicals 002675.SZ | China | $1.59B | 0% | -4% | 15% | 47.2× | 6.0% | -4.3% |
| Sino Biological 301047.SZ | China | $1.60B | +27% | +20% | 17% | 51.6× | 31.1% | -15.1% |
| Anupam Rasayan India ANURAS.NS | India | $1.61B | -3% | +24% | 16% | 49.9× | n/a | n/a |
| Yifan Pharmaceutical 002019.SZ | China | $1.57B | -19% | -5% | 8% | 25.6× | n/a | n/a |
| AstraZeneca Pharma India ASTRAZEN.NS | India | $1.62B | -30% | +30% | 10% | n/a | 42.4% | +23.0% |
| Tonghua Golden-Horse Pharmaceutical Industry 000766.SZ | China | $1.62B | -47% | -18% | 9% | n/a | 33.0% | +0.9% |
| Sarepta Therapeutics SRPT | United States | $1.56B | -15% | -19% | 0% | n/a | -6.8% | +32.4% |
| Consun Pharmaceutical 1681.HK | Hong Kong | $1.65B | +8% | +15% | 35% | 9.2× | -14.9% | +13.5% |
| Zhejiang CONBA Pharmaceutical 600572.SS | China | $1.52B | -4% | +4% | 9% | 16.0× | -6.1% | +1.9% |
| Braveheart Bio BRVE | United States | $1.67B | n/a | n/a | n/a | n/a | n/a | n/a |
| Zhejiang Wolwo Bio-Pharmaceutical 300357.SZ | China | $1.67B | -12% | +7% | 39% | 26.3× | 18.4% | +10.8% |
| JiangXi Tianxin Pharmaceutical 603235.SS | China | $1.52B | -9% | +16% | 24% | n/a | -4.9% | +0.2% |
| ABL Bio 298380.KS | South Korea | $1.51B | -71% | -53% | -201% | n/a | n/a | n/a |
| Indegene INDGN.NS | India | $1.69B | +28% | +36% | 12% | 29.5× | 31.4% | +29.4% |
| Mayinglong Pharmaceutical 600993.SS | China | $1.70B | +2% | +7% | 17% | 17.0× | -3.5% | +6.8% |
| Caplin Point Laboratories CAPLIPOINT.NS | India | $1.70B | +2% | +17% | 31% | 21.4× | 24.3% | +15.7% |
| ApicHope Pharmaceutical 300723.SZ | China | $1.70B | -36% | -28% | -50% | 22.0× | 11.3% | -11.0% |
| Faes Farma FAE.MC | Spain | $1.71B | +6% | +32% | 14% | 17.4× | 3.7% | +9.9% |